NCT00089219View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

May 31, 2006

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
BIOLOGICAL

IFA

vaccine adjuvant

BIOLOGICAL

6MHP

melanoma helper peptides

BIOLOGICAL

GM-CSF

vaccine adjuvant

Trial Locations (1)

22908

University of Virginia Cancer Center, Charlottesville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Virginia

OTHER

NCT00089219 - Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma | Biotech Hunter | Biotech Hunter